Bridgewater Associates LP Sells 21,474 Shares of Phreesia, Inc. (NYSE:PHR)

Bridgewater Associates LP lessened its stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 70.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,971 shares of the company's stock after selling 21,474 shares during the quarter. Bridgewater Associates LP's holdings in Phreesia were worth $226,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. ExodusPoint Capital Management LP boosted its holdings in shares of Phreesia by 448.6% in the 4th quarter. ExodusPoint Capital Management LP now owns 174,971 shares of the company's stock valued at $4,402,000 after buying an additional 143,077 shares during the period. Barclays PLC increased its position in shares of Phreesia by 120.4% in the fourth quarter. Barclays PLC now owns 209,209 shares of the company's stock worth $5,264,000 after acquiring an additional 114,280 shares in the last quarter. Norges Bank acquired a new position in Phreesia during the fourth quarter valued at $2,804,000. Nicholas Company Inc. acquired a new stake in shares of Phreesia during the fourth quarter worth approximately $2,452,000. Finally, State Street Corp increased its position in Phreesia by 7.1% in the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company's stock worth $30,256,000 after purchasing an additional 88,517 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Phreesia

In other news, SVP David Linetsky sold 11,685 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $27.48, for a total transaction of $321,103.80. Following the transaction, the senior vice president now owns 231,271 shares of the company's stock, valued at $6,355,327.08. This represents a 4.81 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Allison C. Hoffman sold 6,556 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $27.48, for a total value of $180,158.88. Following the completion of the transaction, the general counsel now owns 152,361 shares in the company, valued at approximately $4,186,880.28. The trade was a 4.13 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 146,930 shares of company stock valued at $4,067,102. 5.80% of the stock is currently owned by company insiders.

Phreesia Trading Up 0.5 %

Shares of NYSE:PHR traded up $0.13 during midday trading on Friday, reaching $24.72. The company's stock had a trading volume of 163,652 shares, compared to its average volume of 432,897. The firm has a 50 day moving average price of $25.62 and a two-hundred day moving average price of $24.34. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -16.81 and a beta of 0.82. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. KeyCorp lowered their target price on Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Royal Bank of Canada raised shares of Phreesia from a "sector perform" rating to an "outperform" rating and lifted their price target for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Citigroup raised their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, January 10th. DA Davidson dropped their price objective on Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, April 14th. Finally, Piper Sandler reissued an "overweight" rating and issued a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Phreesia presently has a consensus rating of "Buy" and an average target price of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.